Synapse

← Blood Cancer Discovery

Papers in Blood Cancer Discovery

Page 7 · newest first

  1. Altered Oxidative Phosphorylation Confers Vulnerability on IDH1-Mutant Leukemia Cells: Is This Therapeutically Tractable?Blood Cancer Discovery · 2024
  2. Understanding Mechanisms of Response to CAR T-cell Therapy through Single-Cell Sequencing: Insights and ChallengesBlood Cancer Discovery · 2024
  3. Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell LymphomaBlood Cancer Discovery · 2024
  4. Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal HematopoiesisBlood Cancer Discovery · 2023
  5. IDH1 -Mutant Preleukemic Hematopoietic Stem Cells Can Be Eliminated by Inhibition of Oxidative PhosphorylationBlood Cancer Discovery · 2023
  6. Transcriptional Plasticity Drives IMiD and p300 Inhibitor Resistance in Multiple MyelomaBlood Cancer Discovery · 2023
  7. Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)Blood Cancer Discovery · 2023
  8. ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple MyelomaBlood Cancer Discovery · 2023
  9. Criteria for Diagnosis and Molecular Monitoring of NPM1-Mutated AMLBlood Cancer Discovery · 2023
  10. Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor CellsBlood Cancer Discovery · 2023
  11. A Year of Advances in Precision Therapy for Blood CancersBlood Cancer Discovery · 2023
  12. An Embarrassment of Riches: Three FDA-Approved Bispecific Antibodies for Relapsed Refractory Multiple MyelomaBlood Cancer Discovery · 2023
  13. Potent Personalized Venetoclax Partners for Acute Myeloid Leukemia Identified by Ex Vivo Drug ScreeningBlood Cancer Discovery · 2023
  14. IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific AntibodiesBlood Cancer Discovery · 2023
  15. Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple MyelomaBlood Cancer Discovery · 2023
  16. Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia TherapyBlood Cancer Discovery · 2023
  17. Q&A: Riccardo Dalla-Favera on Cancer GeneticsBlood Cancer Discovery · 2023
  18. MRD and Plasma Cell Dynamics after CAR T-cell Therapy in MyelomaBlood Cancer Discovery · 2023
  19. The Inflamed Niche: A Double-Edged Sword in AML?Blood Cancer Discovery · 2023
  20. Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery ApproachesBlood Cancer Discovery · 2023
  21. Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene VicleucelBlood Cancer Discovery · 2023
  22. A Single-Cell Taxonomy Predicts Inflammatory Niche Remodeling to Drive Tissue Failure and Outcome in Human AMLBlood Cancer Discovery · 2023
  23. An MYC-Driven Vicious Circuit Is a Targetable Achilles’ Heel in LymphomaBlood Cancer Discovery · 2023
  24. HTLV-1 bZIP Factor-Induced Reprogramming of Lactate Metabolism and Epigenetic Status Promote Leukemic Cell ExpansionBlood Cancer Discovery · 2023
  25. A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1 -Mutated Myeloid MalignanciesBlood Cancer Discovery · 2023
  26. Defective Immunity Against SARS-CoV-2 Omicron Variants Despite Full Vaccination in Hematologic MalignanciesBlood Cancer Discovery · 2023
  27. The Polyamine–Hypusine Circuit Controls an Oncogenic Translational Program Essential for Malignant Conversion in MYC-Driven LymphomaBlood Cancer Discovery · 2023
  28. METTL3-Mediated m6A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLLBlood Cancer Discovery · 2023
  29. Global Shift in Alternative Splicing and Therapeutic Susceptibilities in Leukemia Driven by METTL3 OverexpressionBlood Cancer Discovery · 2023
  30. Microbiota Influences on Hematopoiesis and Blood Cancers: New Horizons?Blood Cancer Discovery · 2023
  31. The Role of Inflammation in the Initiation and Progression of Myeloid NeoplasmsBlood Cancer Discovery · 2023
  32. Adult Low-Hypodiploid Acute Lymphoblastic Leukemia Evolves from TP53 -Mutated Clonal HematopoiesisBlood Cancer Discovery · 2023
  33. In Vivo Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic TargetBlood Cancer Discovery · 2023
  34. Molecular Evolution of Classic Hodgkin Lymphoma Revealed Through Whole-Genome Sequencing of Hodgkin and Reed Sternberg CellsBlood Cancer Discovery · 2023
  35. Adult Low-Hypodiploid Acute Lymphoblastic Leukemia Emerges from Preleukemic TP53 -Mutant Clonal HematopoiesisBlood Cancer Discovery · 2023
  36. Genetic Modeling of B-cell State Transitions for Rational Design of Lymphoma TherapiesBlood Cancer Discovery · 2022
  37. Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough InfectionsBlood Cancer Discovery · 2022
  38. In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic VulnerabilitiesBlood Cancer Discovery · 2022
  39. Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line TherapyBlood Cancer Discovery · 2022
  40. Distinct Genetically Determined Origins of Myd88 / BCL2 -Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention StrategiesBlood Cancer Discovery · 2022
  41. ETV6 Deficiency Unlocks ERG-Dependent Microsatellite Enhancers to Drive Aberrant Gene Activation in B-Lymphoblastic LeukemiaBlood Cancer Discovery · 2022
  42. A Therapeutically Targetable NOTCH1–SIRT1–KAT7 Axis in T-cell LeukemiaBlood Cancer Discovery · 2022
  43. Extracellular Vesicle Secretion by Leukemia Cells In Vivo Promotes CLL Progression by Hampering Antitumor T-cell ResponsesBlood Cancer Discovery · 2022
  44. Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision MedicineBlood Cancer Discovery · 2022
  45. Anti-spike T-cell and Antibody Responses to SARS-CoV-2 mRNA Vaccines in Patients with Hematologic MalignanciesBlood Cancer Discovery · 2022
  46. Progenitor Hierarchy of Chronic Myelomonocytic Leukemia Identifies Inflammatory Monocytic-Biased Trajectory Linked to Worse OutcomesBlood Cancer Discovery · 2022
  47. Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in MyelomaBlood Cancer Discovery · 2022
  48. CAR T Cells Contend with Myeloma in the Bone Marrow MicroenvironmentBlood Cancer Discovery · 2022
  49. Pharmacogenomic Profiling of Pediatric Acute Myeloid Leukemia to Identify Therapeutic Vulnerabilities and Inform Functional Precision MedicineBlood Cancer Discovery · 2022
  50. Targeting the EIF2AK1 Signaling Pathway Rescues Red Blood Cell Production in SF3B1 -Mutant Myelodysplastic Syndromes With Ringed SideroblastsBlood Cancer Discovery · 2022